iCAD to Present at America's Growth Capital 6th Annual East Coast Emerging Growth Conference

• Press Release
• Source: iCAD, Inc.
• On 9:00 am EDT, Monday September 28, 2009

NASHUA, N.H.--(BUSINESS WIRE)--iCAD, Inc. (NASDAQ: ICAD - News), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced that Ken Ferry, President and Chief Executive Officer and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer, will be presenting a corporate update at America’s Growth Capital’s 6^th Annual East Coast Emerging Growth Conference on October 7, 2009 at 9:50 a.m. (Eastern time) being held at The Westin Copley Place in Boston.

Related Quotes

Symbol	Price	Change
ICAD	1.51	-0.03

{"s" : "icad","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Management will also be available for one-on-one meetings with investors participating in America’s Growth Capital’s 6^th Annual East Coast Emerging Growth Conference. For those who would like to schedule an appointment with iCAD management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at afields@lhai.com or contact your America’s Growth Capital representative.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, over 3,200 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, prostate and in the future, colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “anticipate,” “likely,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.

For iCAD
Darlene Deptula-Hicks, 603-882-5200 x7944
EVP and CFO
ddeptula@icadmed.com
or
For iCAD Investor Relations
Lippert/Heilshorn & Associates
Anne Marie Fields, 212-838-3777 x6604
afields@lhai.com
or
For iCAD Public Relations
MS&L
Liza Heapes, 617-369-8787
liza.heapes@mslworldwide.com